Big pharma scores first victory in IPR battle with Bass and Spangenberg, but the war is far from over
As anyone keeping score will know it’s currently big pharma 2 – Kyle Bass/Erich Spangenberg 0. The decision earlier this week by the Patent Trial and Appeal Board (PTAB) not to institute inter partes reviews of two patents owned by pharmaceutical…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.